OncoMatch/Clinical Trials/NCT06107686
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Is NCT06107686 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies YL202 should be intravenously infused for nsclc.
Treatment: YL202 should be intravenously infused — This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Breast Carcinoma
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: HER3-targeted therapy
prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs])
Cannot have received: CAR-T cell therapy
chimeric antigen receptor T-cell immunotherapy (CAR-T)
Cannot have received: topoisomerase I inhibitor
Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors
Cannot have received: antibody-drug conjugate
Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors
Cannot have received: allogeneic bone marrow transplantation
Prior treatment with allogeneic bone marrow transplantation
Cannot have received: solid organ transplantation
Prior treatment with ... solid organ transplantation
Lab requirements
Blood counts
The function of organs and bone marrow meets the requirements within 7 days before the first dose.
Kidney function
The function of organs and bone marrow meets the requirements within 7 days before the first dose.
Liver function
The function of organs and bone marrow meets the requirements within 7 days before the first dose.
The function of organs and bone marrow meets the requirements within 7 days before the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06107686 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HER3-targeted therapy, CAR-T cell therapy, topoisomerase I inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify